ConductScience.org, home

Gene · 6241

RRM2: ribonucleotide reductase regulatory subunit M2

11 sourcesgene-search-2026-11-11-0.1.0

Download JSON
Cite this record

ConductScience Library. RRM2: ribonucleotide reductase regulatory subunit M2. Genes, record 6241. Release gene-search-2026-11-11-0.1.0, 11 Nov 2026. https://conductscience.org/library/genes/6241

On this page

Gene

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

Symbol
RRM2
HGNC
Name
ribonucleotide reductase regulatory subunit M2
HGNC
NCBI Gene ID
6241
NCBI Gene
HGNC ID
HGNC:10452
HGNC
Ensembl
ENSG00000171848
NCBI Gene
Aliases
C2orf48, FLJ25102, R2, RR2, RR2M
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P31350Ribonucleoside-diphosphate reductase subunit M23895Ensembl, GeneID, HGNC

Source UniProt

Patents66

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1461937P31350Espacenet
EP 4650780 A22025-11-194179P31350Espacenet
EP 4641202 A22025-10-294785P31350Espacenet
JP 2025529142 A2025-09-043785P31350Espacenet
US 12371689 B22025-07-293785P31350Espacenet
JP 2025517970 A2025-06-124179P31350Espacenet
KR 1020250017231 A2025-02-044785P31350Espacenet
US 12208133 B22025-01-284P31350Espacenet
EP 4310198 A22024-01-2436P31350Espacenet
US 11446398 B22022-09-2073870P31350Espacenet

1 to 10 of 66

See all 66 patents

Drugs10

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
CLOFARABINECHEMBL1750Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
FLUDARABINE PHOSPHATECHEMBL1096882Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
GALLIUM NITRATECHEMBL1200983Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
GEMCITABINECHEMBL888Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
GEMCITABINE HYDROCHLORIDECHEMBL1637Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
GTI-2040CHEMBL4297763Ribonucleotide reductase small subunit mRNA antisense inhibitorANTISENSE INHIBITORChEMBL
HYDROXYUREACHEMBL467Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
MOTEXAFIN GADOLINIUMCHEMBL3544910Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
TEZACITABINECHEMBL3989496Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
TEZACITABINE ANHYDROUSCHEMBL2105467Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL

Trials3,154

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07604766GEMCITABINEPHASE3ClinicalTrials.gov
NCT07603557FLUDARABINE PHOSPHATEPHASE2ClinicalTrials.gov
NCT07602140GEMCITABINEPHASE2ClinicalTrials.gov
NCT07598318GEMCITABINEPHASE2/PHASE3ClinicalTrials.gov
NCT07579195GEMCITABINEPHASE1/PHASE2ClinicalTrials.gov
NCT07575191GEMCITABINEPHASE1/PHASE2ClinicalTrials.gov
NCT07570849GEMCITABINEPHASE2ClinicalTrials.gov
NCT07570823GEMCITABINEPHASE3ClinicalTrials.gov
NCT07570017GEMCITABINEPHASE1ClinicalTrials.gov
NCT07569679GEMCITABINEPHASE2ClinicalTrials.gov

1 to 10 of 3,154

See all 3,154 trials

NIH grants2,322

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal year
P30CA016672Cancer Center Support Grant262025
P30CA008748Cancer Center Support Grant252025
P30CA033572Cancer Center Support Grant122025
P30CA016086Cancer Center Support Grant112025
P30CA086862Cancer Center Support Grant112025
P30CA010815Consolidated Basic Cancer Research Program102025
R01GM070503Molecular Recognition During Pre-mRNA Splicing102025
P30CA016058Cancer Center Support Grant92025
ZIAAG000511Post-transcriptional control of Proliferation, Stress Response & Carcinogenesis92025
P01CA013106Targeting Transcription and Splicing in Cancer82025

1 to 10 of 2,322Source NIH's project files

See all 2,322 nih grants

Papers4,414

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42821473PubTator, text miningPubMed
42817800PubTator, text miningPubMed
42794427PubTator, text miningPubMed
42732660PubTator, text miningPubMed
42726806PubTator, text miningPubMed
42708612PubTator, text miningPubMed
42703413PubTator, text miningPubMed
42667808PubTator, text miningPubMed
42664521PubTator, text miningPubMed
42661875PubTator, text miningPubMed

1 to 10 of 4,414

See all 4,414 papers

Sources 11

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNone stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GeneNone named. Public domain as US government information
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/6241

GET https://conductscience.org/api/genes/v1/6241/patents?page=2